RESUMEN
Immunological complexity in atherosclerosis warrants targeted treatment of specific inflammatory cells that aggravate the disease. With the initiation of large phase III trials investigating immunomodulatory drugs for atherosclerosis, cardiovascular disease treatment enters a new era. We here propose a radically different approach: implementing and evaluating in vivo a combinatorial library of nanoparticles with distinct physiochemical properties and differential immune cell specificities. The library's nanoparticles are based on endogenous high-density lipoprotein, which can preferentially deliver therapeutic compounds to pathological macrophages in atherosclerosis. Using the apolipoprotein E-deficient (Apoe-/-) mouse model of atherosclerosis, we quantitatively evaluated the library's immune cell specificity by combining immunological techniques and in vivo positron emission tomography imaging. Based on this screen, we formulated a liver X receptor agonist (GW3965) and abolished its liver toxicity while still preserving its therapeutic function. Screening the immune cell specificity of nanoparticles can be used to develop tailored therapies for atherosclerosis and other inflammatory diseases.
Asunto(s)
Aterosclerosis/tratamiento farmacológico , Aterosclerosis/inmunología , Inmunoterapia , Nanopartículas/química , Animales , Antiinflamatorios , Apolipoproteínas E/deficiencia , Aterosclerosis/patología , Autorradiografía , Benzoatos/agonistas , Benzoatos/química , Bencilaminas/agonistas , Bencilaminas/química , Modelos Animales de Enfermedad , Sistemas de Liberación de Medicamentos/métodos , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Lipoproteínas HDL/química , Lipoproteínas HDL/farmacología , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Imagen Molecular , Nanomedicina , Nanopartículas/metabolismo , Tomografía de Emisión de Positrones/métodos , ARN Mensajero/metabolismoRESUMEN
Opioids are the most effective and widely used drugs for pain treatment. Morphine is an archetypal opioid and is an opioid receptor agonist. Unfortunately, the clinical usefulness of morphine is limited by adverse effects such as analgesic tolerance and addiction. Therefore, it is important to study the development of novel opioid agonists as part of pain control. The analgesic effects of opioids are mediated by three opioid receptors, namely opioid µ-, δ-, and κ-receptors. They belong to the G protein-coupled receptor superfamily and are coupled to Gi proteins. In the present study, we developed a ligand screening system to identify novel opioid µ-receptor agonists that measures [(35)S]GTPγS binding to cell membrane fractions prepared from the fat body of transgenic silkworms expressing µ-receptor-Gi1α fusion protein. We screened the RIKEN Natural Products Depository (NPDepo) chemical library, which contains 5848 compounds, and analogs of hit compounds. We successfully identified a novel, structurally unique compound, that we named GUM1, with agonist activity for the opioid µ-receptor (EC50 of 1.2 µM). The Plantar Test (Hargreaves' Method) demonstrated that subcutaneous injection of 3mg/kg of GUM1 into wild-type rats significantly extended latency time. This extension was also observed in a rat model of morphine tolerance and was inhibited by pre-treatment of naloxone. The unique molecular skeleton of GUM1 makes it an attractive molecule for further ligand-opioid receptor binding studies.
Asunto(s)
Bencilaminas/agonistas , Bencilaminas/farmacología , Productos Biológicos/farmacología , Piranos/agonistas , Piranos/farmacología , Receptores Opioides mu/agonistas , Analgésicos Opioides/agonistas , Analgésicos Opioides/farmacología , Animales , Animales Modificados Genéticamente , Bombyx , Tolerancia a Medicamentos , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Humanos , Masculino , Dimensión del Dolor/efectos de los fármacos , Ensayo de Unión Radioligante , Ratas , Receptores Opioides mu/genética , Radioisótopos de Azufre/metabolismoRESUMEN
INTRODUCTION: Combinations of anticoagulants might be beneficial in some patients with sepsis, but most anticoagulants require specific clotting assays for monitoring. Thrombin generation assay, however, is a global function test of hemostasis. MATERIALS AND METHODS: We performed an in vitro investigation of the respective effects of recombinant human activated protein C (rhAPC) alone and in combination with either melagatran (a new direct thrombin inhibitor), unfractionated heparin (UH) or low molecular weight heparin (LMWH) in varying concentrations on the thrombin generation (TG) using the calibrated automated thrombography. RESULTS: RhAPC, UH, LMWH and melagatran dose-dependently prolonged the lag time and the time to peak, and significantly suppressed the endogenous thrombin potential (ETP). Combined application of rhAPC with either melagatran, UH or LMWH induced an additive prolongation of the lag time; this effect was more pronounced in a combination of rhAPC with UH or LMWH. CONCLUSION: In our in vitro study adding either melagatran, UH or LMWH augmented the capacity of rhAPC to suppress thrombin generation in human plasma. These findings suggest that patients with severe sepsis might benefit from a treatment with combinations of anticoagulant agents.